177 related articles for article (PubMed ID: 32185579)
1. Optimal Sampling Strategies for Irinotecan (CPT-11) and its Active Metabolite (SN-38) in Cancer Patients.
Karas S; Etheridge AS; Tsakalozou E; Ramírez J; Cecchin E; van Schaik RHN; Toffoli G; Ratain MJ; Mathijssen RHJ; Forrest A; Bies RR; Innocenti F
AAPS J; 2020 Mar; 22(3):59. PubMed ID: 32185579
[TBL] [Abstract][Full Text] [Related]
2. Population pharmacokinetic model of irinotecan and its four main metabolites in patients treated with FOLFIRI or FOLFIRINOX regimen.
Deyme L; Barbolosi D; Mbatchi LC; Tubiana-Mathieu N; Ychou M; Evrard A; Gattacceca F
Cancer Chemother Pharmacol; 2021 Aug; 88(2):247-258. PubMed ID: 33912999
[TBL] [Abstract][Full Text] [Related]
3. Limited sampling models for simultaneous estimation of the pharmacokinetics of irinotecan and its active metabolite SN-38.
Chabot GG
Cancer Chemother Pharmacol; 1995; 36(6):463-72. PubMed ID: 7554037
[TBL] [Abstract][Full Text] [Related]
4. Population pharmacokinetics and pharmacodynamics of irinotecan (CPT-11) and active metabolite SN-38 during phase I trials.
Chabot GG; Abigerges D; Catimel G; Culine S; de Forni M; Extra JM; Mahjoubi M; Hérait P; Armand JP; Bugat R
Ann Oncol; 1995 Feb; 6(2):141-51. PubMed ID: 7786822
[TBL] [Abstract][Full Text] [Related]
5. Population pharmacokinetic model of irinotecan and its metabolites in patients with metastatic colorectal cancer.
Oyaga-Iriarte E; Insausti A; Sayar O; Aldaz A
Eur J Clin Pharmacol; 2019 Apr; 75(4):529-542. PubMed ID: 30610273
[TBL] [Abstract][Full Text] [Related]
6. Effects of bevacizumab on plasma concentration of irinotecan and its metabolites in advanced colorectal cancer patients receiving FOLFIRI with bevacizumab as second-line chemotherapy.
Horita Y; Yamada Y; Hirashima Y; Kato K; Nakajima T; Hamaguchi T; Shimada Y
Cancer Chemother Pharmacol; 2010 Feb; 65(3):467-71. PubMed ID: 19554330
[TBL] [Abstract][Full Text] [Related]
7. Assessment of exposure risk of irinotecan and its active metabolite, SN-38, through perspiration during chemotherapy.
Irie K; Okada A; Masuda Y; Fukushima K; Sugioka N; Okuda C; Hata A; Kaji R; Okada Y; Katakami N; Fukushima S
J Oncol Pharm Pract; 2019 Jun; 25(4):865-868. PubMed ID: 29651916
[TBL] [Abstract][Full Text] [Related]
8. Enzyme and Transporter Kinetics for CPT-11 (Irinotecan) and SN-38: An Insight on Tumor Tissue Compartment Pharmacokinetics Using PBPK.
Fan Y; Mansoor N; Ahmad T; Wu ZX; Khan RA; Czejka M; Sharib S; Ahmed M; Chen ZS; Yang DH
Recent Pat Anticancer Drug Discov; 2019; 14(2):177-186. PubMed ID: 30760193
[TBL] [Abstract][Full Text] [Related]
9. Simple and rapid determination of irinotecan and its metabolite SN-38 in plasma by high-performance liquid-chromatography: application to clinical pharmacokinetic studies.
Escoriaza J; Aldaz A; Castellanos C; Calvo E; Giráldez J
J Chromatogr B Biomed Sci Appl; 2000 Apr; 740(2):159-68. PubMed ID: 10821401
[TBL] [Abstract][Full Text] [Related]
10. Integration of DNA sequencing with population pharmacokinetics to improve the prediction of irinotecan exposure in cancer patients.
Karas S; Etheridge AS; Nickerson DA; Cox NJ; Mohlke KL; Cecchin E; Toffoli G; Mathijssen RHJ; Forrest A; Bies RR; Innocenti F
Br J Cancer; 2022 Mar; 126(4):640-651. PubMed ID: 34703007
[TBL] [Abstract][Full Text] [Related]
11. Phase I and pharmacokinetic study of irinotecan (CPT-11) administered daily for three consecutive days every three weeks in patients with advanced solid tumors.
Catimel G; Chabot GG; Guastalla JP; Dumortier A; Cote C; Engel C; Gouyette A; Mathieu-Boué A; Mahjoubi M; Clavel M
Ann Oncol; 1995 Feb; 6(2):133-40. PubMed ID: 7786821
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetic assessment of irinotecan, SN-38, and SN-38-glucuronide: a substudy of the FIRIS study.
Satoh T; Yasui H; Muro K; Komatsu Y; Sameshima S; Yamaguchi K; Sugihara K
Anticancer Res; 2013 Sep; 33(9):3845-53. PubMed ID: 24023318
[TBL] [Abstract][Full Text] [Related]
13. A limited sampling strategy to estimate the pharmacokinetic parameters of irinotecan and its active metabolite, SN-38, in patients with metastatic digestive cancer receiving the FOLFIRI regimen.
Poujol S; Pinguet F; Ychou M; Abderrahim AG; Duffour J; Bressolle FM
Oncol Rep; 2007 Dec; 18(6):1613-321. PubMed ID: 17982652
[TBL] [Abstract][Full Text] [Related]
14. Relationship between the pharmacokinetics of irinotecan and diarrhea during combination chemotherapy with cisplatin.
Kudoh S; Fukuoka M; Masuda N; Yoshikawa A; Kusunoki Y; Matsui K; Negoro S; Takifuji N; Nakagawa K; Hirashima T
Jpn J Cancer Res; 1995 Apr; 86(4):406-13. PubMed ID: 7775263
[TBL] [Abstract][Full Text] [Related]
15. Phase I clinical and pharmacokinetic study of irinotecan, fluorouracil, and leucovorin in patients with advanced solid tumors.
Saltz LB; Kanowitz J; Kemeny NE; Schaaf L; Spriggs D; Staton BA; Berkery R; Steger C; Eng M; Dietz A; Locker P; Kelsen DP
J Clin Oncol; 1996 Nov; 14(11):2959-67. PubMed ID: 8918493
[TBL] [Abstract][Full Text] [Related]
16. A fast method for the detection of irinotecan in plasma samples by combining solid phase extraction and differential pulse voltammetry.
Bonazza G; Tartaggia S; Toffoli G; Polo F; Daniele S
Anal Bioanal Chem; 2020 Mar; 412(7):1585-1595. PubMed ID: 31982924
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics of irinotecan and its metabolites in pediatric cancer patients: a report from the children's oncology group.
Thompson PA; Gupta M; Rosner GL; Yu A; Barrett J; Bomgaars L; Bernstein ML; Blaney SM; Mondick J
Cancer Chemother Pharmacol; 2008 Nov; 62(6):1027-37. PubMed ID: 18278496
[TBL] [Abstract][Full Text] [Related]
18. A limited sampling model for estimating pharmacokinetics of CPT-11 and its metabolite SN-38.
Sasaki Y; Mizuno S; Fujii H; Ohtsu T; Wakita H; Igarashi T; Itoh K; Sekine I; Miyata Y; Saijo N
Jpn J Cancer Res; 1995 Jan; 86(1):117-23. PubMed ID: 7737903
[TBL] [Abstract][Full Text] [Related]
19. Clinical pharmacokinetics of irinotecan.
Chabot GG
Clin Pharmacokinet; 1997 Oct; 33(4):245-59. PubMed ID: 9342501
[TBL] [Abstract][Full Text] [Related]
20. Efficient sampling strategies for forecasting pharmacokinetic parameters of irinotecan (CPT-11): implication for area under the concentration-time curve monitoring.
Nakashima H; Lieberman R; Karato A; Arioka H; Ohmatsu H; Nomura N; Shiraishi J; Tamura T; Eguchi K; Shinkai T
Ther Drug Monit; 1995 Jun; 17(3):221-9. PubMed ID: 7624917
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
